|Targets||CDK | CK1|
|Description||The hydrochloride salt form of (R)-DRF053, which is a cdk/CK1 inhibitor and could be used in studies in the cancer treatment with combinations of CDK kinase and ERK inhibitors.|
|Purity||≥98% by HPLC|
RGB-286638 is a novel CDK inhibitor. It inhibited several tyrosine and serine/threonine non-CDK enzymes, i.e. GSK-3β, TAK1, AMPK, Jak2, MEK1. It demonstrated eq...
NVP-LCQ195 is a small molecule heterocyclic inhibitor of CDK1, CDK2, CDK3 and CDK5. It induced cell cycle arrest and eventual apoptotic cell death of MM cells, ...
CDKI-73 was cytotoxic to all of the CLL samples tested (n = 38) with a mean LD50 value of 0.08μM ± 0.10 μM following exposure to drug for 48h. In contrast, norm...
Riviciclib, also known as P276-00, is a novel CDK1, CDK4 and CDK9 inhibitor with IC50 of 79 nM, 63 nM and 20 nM, respectively. P276-00 selectively binds to and ...
D4476 is a potent, selective ATP-competitive inhibitor of CK1 (casein kinase 1).
Palbociclib is an orally available cyclin-dependent kinase (CDK) inhibitor with potential antineoplastic activity. Palbociclib selectively inhibits cyclin-depen...
WHI-P180 moderately inhibited ABCG2 function, exhibiting weak phototoxicity. The elimination half-life of WHI-P180 in CD-1 mice (BALB/ c mice) following i.v., i...
CCT-251921 has been found to be a CDK inhibitor that could be significant in the studies of colorectal cancer.